Literature DB >> 29663017

Cyclic nucleotide phosphodiesterases: potential therapeutic targets for alcohol use disorder.

Rui-Ting Wen1, Fang-Fang Zhang2, Han-Ting Zhang3,4.   

Abstract

Alcohol use disorder (AUD), which combines the criteria of both alcohol abuse and dependence, contributes as an important causal factor to multiple health and social problems. Given the limitation of current treatments, novel medications for AUD are needed to better control alcohol consumption and maintain abstinence. It has been well established that the intracellular signal transduction mediated by the second messengers cyclic AMP (cAMP) and cyclic GMP (cGMP) crucially underlies the genetic predisposition, rewarding properties, relapsing features, and systemic toxicity of compulsive alcohol consumption. On this basis, the upstream modulators phosphodiesterases (PDEs), which critically control intracellular levels of cyclic nucleotides by catalyzing their degradation, are proposed to play a role in modulating alcohol abuse and dependent process. Here, we highlight existing evidence that correlates cAMP and cGMP signal cascades with the regulation of alcohol-drinking behavior and discuss the possibility that PDEs may become a novel class of therapeutic targets for AUD.

Entities:  

Keywords:  Alcohol dependence; Alcohol use disorder (AUD); Central nervous system; Phosphodiesterase (PDE); cAMP; cGMP

Mesh:

Substances:

Year:  2018        PMID: 29663017      PMCID: PMC5949271          DOI: 10.1007/s00213-018-4895-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  152 in total

1.  Lack of changes in beta-endorphin plasma levels after repeated treatment with fluoxetine: possible implications for the treatment of alcoholism--a pilot study.

Authors:  J Zalewska-Kaszubska; D Górska; W Dyr; E Czarnecka
Journal:  Pharmazie       Date:  2008-04       Impact factor: 1.267

2.  The phosphodiesterase-4 inhibitor roflumilast decreases ethanol consumption in C57BL/6J mice.

Authors:  Xin Liu; Pi-Da Hao; Ming-Feng Yang; Jing-Yi Sun; Lei-Lei Mao; Cun-Dong Fan; Zong-Yong Zhang; Da-Wei Li; Xiao-Yi Yang; Bao-Liang Sun; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2017-05-06       Impact factor: 4.530

3.  3',5'-cyclic nucleotide phosphodiesterase 11A: localization in human tissues.

Authors:  K Loughney; J Taylor; V A Florio
Journal:  Int J Impot Res       Date:  2005 Jul-Aug       Impact factor: 2.896

4.  Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues.

Authors:  Viktor Lakics; Eric H Karran; Frank G Boess
Journal:  Neuropharmacology       Date:  2010-05-21       Impact factor: 5.250

Review 5.  Alcoholism: allostasis and beyond.

Authors:  George F Koob
Journal:  Alcohol Clin Exp Res       Date:  2003-02       Impact factor: 3.455

Review 6.  The persistence of maladaptive memory: addiction, drug memories and anti-relapse treatments.

Authors:  Amy L Milton; Barry J Everitt
Journal:  Neurosci Biobehav Rev       Date:  2012-01-24       Impact factor: 8.989

7.  The involvement of type IV phosphodiesterases in cocaine-induced sensitization and subsequent pERK expression in the mouse nucleus accumbens.

Authors:  Amy C Janes; Kathleen M Kantak; James A Cherry
Journal:  Psychopharmacology (Berl)       Date:  2009-07-09       Impact factor: 4.530

8.  The phosphodiesterase-4 inhibitor rolipram attenuates heroin-seeking behavior induced by cues or heroin priming in rats.

Authors:  Miaojun Lai; Huaqiang Zhu; Anna Sun; Dingding Zhuang; Dan Fu; Weisheng Chen; Han-Ting Zhang; Wenhua Zhou
Journal:  Int J Neuropsychopharmacol       Date:  2014-05-15       Impact factor: 5.176

9.  Phosphodiesterase 4 inhibitors, rolipram and diazepam block the adaptive changes observed during morphine withdrawal in the heart.

Authors:  Ana González-Cuello; Lorenzo Sánchez; Jesús Hernández; M Teresa Castells; M Victoria Milanés; M Luisa Laorden
Journal:  Eur J Pharmacol       Date:  2007-06-09       Impact factor: 4.432

10.  Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial.

Authors:  Lara A Ray; Spencer Bujarski; Steve Shoptaw; Daniel Jo Roche; Keith Heinzerling; Karen Miotto
Journal:  Neuropsychopharmacology       Date:  2017-01-16       Impact factor: 8.294

View more
  7 in total

1.  Inhibition of phosphodiesterase 2 by Bay 60-7550 decreases ethanol intake and preference in mice.

Authors:  Jing Shi; Huaxia Liu; Jianchun Pan; Jie Chen; Nianping Zhang; Kaiping Liu; Ning Fei; James M O'Donnell; Han-Ting Zhang; Ying Xu
Journal:  Psychopharmacology (Berl)       Date:  2018-06-07       Impact factor: 4.530

2.  Apremilast regulates acute effects of ethanol and other GABAergic drugs via protein kinase A-dependent signaling.

Authors:  Yuri A Blednov; Cecilia M Borghese; Michael P Dugan; Swetak Pradhan; Thanvi M Thodati; Nikhita R Kichili; R Adron Harris; Robert O Messing
Journal:  Neuropharmacology       Date:  2020-07-29       Impact factor: 5.250

Review 3.  Neuroimmune signaling in alcohol use disorder.

Authors:  Emma K Erickson; Emily K Grantham; Anna S Warden; R A Harris
Journal:  Pharmacol Biochem Behav       Date:  2018-12-24       Impact factor: 3.533

Review 4.  Neuroimmune Mechanisms as Novel Treatment Targets for Substance Use Disorders and Associated Comorbidities.

Authors:  Mark D Namba; Jonna M Leyrer-Jackson; Erin K Nagy; M Foster Olive; Janet L Neisewander
Journal:  Front Neurosci       Date:  2021-04-15       Impact factor: 4.677

5.  Effects of chronic voluntary alcohol consumption on PDE10A availability: a longitudinal behavioral and [18F]JNJ42259152 PET study in rats.

Authors:  Bart de Laat; Yvonne E Kling; Gwen Schroyen; Maarten Ooms; Jacob M Hooker; Guy Bormans; Koen Van Laere; Jenny Ceccarini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-17       Impact factor: 9.236

6.  The foraging gene affects alcohol sensitivity, metabolism and memory in Drosophila.

Authors:  Anne S Oepen; Jamie L Catalano; Reza Azanchi; Karla R Kaun
Journal:  J Neurogenet       Date:  2021-06-07       Impact factor: 1.696

Review 7.  Immune treatments for alcohol use disorder: A translational framework.

Authors:  Lindsay R Meredith; Elizabeth M Burnette; Erica N Grodin; Michael R Irwin; Lara A Ray
Journal:  Brain Behav Immun       Date:  2021-07-31       Impact factor: 19.227

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.